Gyre Therapeutics
GYRE
69 hedge funds and large institutions have $87.7M invested in Gyre Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 29 reducing their positions, and 30 closing their positions.
4,200% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $43K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.93% less ownership
Funds ownership: 9.54% → 8.61% (-0.93%)
22% less capital invested
Capital invested by funds: $113M → $87.7M (-$25.2M)
22% less funds holding
Funds holding: 89 → 69 (-20)
38% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 29
67% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 30
Top Buyers
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$2.99M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.87M |
| 3 |
Renaissance Technologies
New York
|
+$2.05M |
| 4 |
Millennium Management
New York
|
+$1.14M |
| 5 |
RC
RBF Capital
San Francisco,
California
|
+$724K |
Top Sellers
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.3M |
| 2 |
BlackRock
New York
|
-$6.26M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.53M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.16M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.05M |
GYRE Hedge Fund Activity: Q2 2021 in Review
69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2021, worth a combined $87.7M — down 22% from $113M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of GYRE and 10 opened new positions — a net loss of 20 holders — while 29 trimmed existing stakes and 18 added.
The largest buyer was 22NW LP, adding an estimated $2.99M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.3M sold.
- 69 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2021, down from 89 in Q1 2021.
- Funds reported $87.7M of Gyre Therapeutics stock for Q2 2021, down 22% quarter-over-quarter.
- 10 funds opened new Gyre Therapeutics positions in Q2 2021 and 30 closed out, a net change of -20 holders.
- The largest Gyre Therapeutics buyer in Q2 2021 was 22NW LP, an estimated $2.99M added.
- The largest Gyre Therapeutics seller in Q2 2021 was Opaleye Management, an estimated $6.3M sold.
Based on aggregated 13F filings for Q2 2021.